MAP2K1 and cancer: Therefore, this pivotal intersectional position of MEK1/2 makes it an attractive antitumor target in cancer therapy, including EC.[6] Currently, several MEK inhibitors have been developed, and some have shown remarkable potency and selectivity during clinical evaluation.[7] However, patients treated with RAF or MEK inhibitors frequently develop drug resistance within several months.[8] Given this situation, researchers continue to pursue approaches that can reverse drug resistance, and develop innovative combination strategies with other targeted therapeutics to overcome these challenges.[9]